Exploring structural features of EGFR–HER2 dual inhibitors as anti-cancer agents using G-QSAR approach
Author:
Affiliation:
1. Bioinformatics Division, ICMR-National Institute of Cancer Prevention and Research, Noida, India
Publisher
Informa UK Limited
Subject
Cell Biology,Molecular Biology,Biochemistry
Link
https://www.tandfonline.com/doi/pdf/10.1080/10799893.2019.1660896
Reference36 articles.
1. Dual or multi-targeting inhibitors: The next generation anticancer agents
2. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
3. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
4. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
5. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Virtual screening, XGBoost based QSAR modelling, Molecular Docking and Molecular Dynamics Simulation approach to discover a new inhibitor targeting ErbB1 Protein;2024-06-04
2. GraphEGFR: Multi‐task and transfer learning based on molecular graph attention mechanism and fingerprints improving inhibitor bioactivity prediction for EGFR family proteins on data scarcity;Journal of Computational Chemistry;2024-05-07
3. LigEGFR: Spatial graph embedding and molecular descriptors assisted bioactivity prediction of ligand molecules for epidermal growth factor receptor on a cell line-based dataset;2020-12-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3